JCB logo
MBL International Tel: 800.200.5459 CLICK HERE
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 21 April 2003. doi:10.1083/jcb1612iti5
This Article
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0021-9525/2003/4/219-b $5.00
The Journal of Cell Biology, Volume 161, Number 2, 219-b-219


In This Issue

Say NO to insulin


NO regulates association of GK (yellow) with insulin secretory granules (blue).

Insulin stimulates its own secretion from pancreatic ß cells through rapid nitrosylation of glucokinase (GK), according to results by Rizzo and Piston on page 243.

When glucose levels are low, an inhibited form of GK associates with insulin-containing granules in pancreatic ß cells. Rizzo and Piston have determined that this localization is mediated through interaction with neuronal nitric oxide synthase (nNOS). Insulin treatment disrupted this association through nitrosylation of a GK cysteine residue. Activation of nNOS and the resulting nitrosylation of GK may be mediated through a rise in intracellular calcium, a known response of ß cells to insulin treatment. Release of the enzyme into the cytoplasm and the accompanying conformational change—both of which required NO production— activated GK.

GK induces secretion of the granules, thus promoting local increases in insulin levels. A recently developed drug for the treatment of type II diabetes is a GK activator. The new results suggest that the drug may activate GK by preventing granule binding. Piston plans to test this possibility in the near future. {blacksquare}



Nicole LeBrasseur

lebrasn{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Regulation of ß cell glucokinase by S-nitrosylation and association with nitric oxide synthase
Mark A. Rizzo and David W. Piston
J. Cell Biol. 2003 161: 243-248. [Abstract] [Full Text] [PDF]




This Article
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents